1 Determination of vancomycin pharmacokinetic/pharmacodynamic target and 2 individualized dosing regimen recommendation in ICU neonates 3 Zhe Tang, a Wei-wei Shuai, Jing-jing Li, Yan-xia Yu, Miao Qian, Xin Tong, Jing Cao, # 4 5 Zheng Jiao d# 6 ^aDepartment of Pharmacy, Women's Hospital of Nanjing Medical University, Nanjing 7 Maternity and Child Health Care Hospital, Nanjing, China 8 ^bDepartment of Neonatology, Women's Hospital of Nanjing Medical University, Nanjing 9 Maternity and Child Health Care Hospital, Nanjing, China 10 ^cDepartment of Pharmacy, Suzhou Municipal Hospital, Suzhou, China 11 ^dDepartment of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, 12 Shanghai, China 13 14 Running Head: PK/PD target of vancomycin in ICU neonates 15 16 #Correspondence 17 Zheng Jiao, jiaozhen@online.sh.cn 18 Jing Cao, njfycj@163.com. 19

ABSTRACT

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

A Bayesian-derived area-under-the-curve from 0 to 24 h to minimum inhibitory concentration (AUC₂₄/MIC) of 400 to 600 has been recommended as the pharmacokinetic/pharmacodynamic (PK/PD) target of vancomycin (VAN) treatment in adults. However, limited data exists in neonates to support this target. Therefore, this study aimed: (i) to develop a population PK model to characterize significant covariates and to estimate AUC; (ii) to determine the neonatal PK/PD target of VAN and potential influence factors on this target; (iii) to design neonatal VAN recommendation based on the evaluated target. A single center retrospective observational cohort study was conducted. A population PK model was established by using Monolix 2019R2. Acute kidney injury (AKI) for all 182 patients were screened to determine the upper limit of VAN exposure. Clinical efficacy of 42 patients with blood culture proved staphylococcal sepsis was analyzed, and the threshold in predicting efficacy was developed as the lower limit of exposure. AUC₂₄ ≥ 623 (mg·h)/liter and concomitant use of VAS were independent risks for AKI. When adjusted by current body weight (cWT) < 1.3 kg, AUC₂₄/MIC < 242 was highly correlated with treatment failure. AUC₂₄/MIC of 250 to 600 with MIC assumed to 1 mg/liter was set as the optimal PK/PD target in neonates then dosing recommendation was designed. In conclusion, AUC₂₄/MIC is a good predictor for VAN toxicity and efficacy in neonates. The designed regimens are valuable for neonatal individualized dosing in ICU setting. (This study has been registered at chictr.org.cn under identifier ChiCTR1900027919.)

Key words: vancomycin, neonate, PK/PD, population PK modeling, AKI, efficacy

INTRODUCTION

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

Neonates are predisposed to late-onset neonatal sepsis (LOS) owing to their compromised immune function and medical interventions. Staphylococcus aureus and other Staphylococcus spp. are predominant pathogens leading to LOS. VAN, a glycopeptide antibiotic developed many years ago, remains the agent of choice against staphylococcal sepsis for patients in neonatal intensive care units (NICU) (1). AUC₂₄/MIC has been identified as the most predictive PK/PD index of VAN treatment (2). Trough-based target is no longer recommended due to studies of efficacy and nephrotoxicity (3). Moreover, this target is regarded unreliable because of its intervaldependent nature (4, 5). American Society of Health-System Pharmacists (ASHP) has advocated a Bayesian-derived AUC/MIC ratio of 400 to 600 (assuming MIC of 1 mg/liter) as the target for adults infected by methicillin-resistant S. aureus (MRSA) (3). However, there is paucity of evidence in literature to guide the optimal exposure target in neonates. VAN is a well-kwon potential renal toxic agent, while the breakpoint of its exposure in predicting AKI, to our knowledge, has not been reported in neonates. AUC > 800 (mg·h)/liter was considered associated with the increased risk of nephrotoxicity in children (6). This target was often used as the upper limit of VAN exposure to design dosing regimen in neonates without solid validation in clinical studies (7). Additional risk of unnecessary overexposure maybe arises in this condition. Controversies remain in VAN exposure required for clinical efficacy. AUC/MIC > 400 was reported not related to improved outcomes and a relationship between AUC/MIC and

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

treatment failure failed to be established in pediatrics as well (8). Whether AUC/MIC > 400 is a necessary exposure for neonates is urgent to be verified. Therefore, this study aimed: (i) to develop a population PK model to characterize significant covariates and to estimate AUC; (ii) to determine the neonatal PK/PD target of VAN and potential influence factors on this target; (iii) to design neonatal VAN recommendation based on the evaluated target to facilitate individualized dosing in regular NICU practice. RESULTS **Study population** There were 185 neonates administered by intermittent intravenous infusion of VAN under therapeutic drug monitoring (TDM) in NICU of Nanjing Maternity and Child Health Care Hospital from 1st January 2016 to 31st December 2019. One hundred and eighty-two patients were eligible for this study with 286 trough and 125 peak concentrations monitored within the calibration range of analytical instrument. Two patients with incomplete clinical data and the sole patient suffered from hematological malignancy were excluded. The study flow was presented in Fig. 1. All of patients were diagnosed as neonatal sepsis by clinical physicians with empirical VAN application. About half of patients were co-medicated meropenem (MEM) and 36 individuals were received vasoactive drugs (VAS). The major comorbidities comprised patent ductus arteriosus (PDA), pneumonia, bronchopulmonary dysplasia (BDP),

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

meningitis, neonatal necrotic enterocolitis (NEC) and persistent pulmonary hypertension of newborn (PPHN). The mortality of the whole population was 15 (8.24%). **Population PK modeling** A population PK model was developed to estimate PK parameters of patients. One compartment model with first-order elimination was enough to fit the data set. A proportional model was chosen as the residual model. Various models, including base model (Model I), simple exponent model (Model II), sigmoid function model (Model III), age-dependent exponent (ADE) model (Model IV) and body weight-dependent exponent (BDE) model (Model V), were investigated to screen the covariates of body size (9). The detailed process was summarized in Table S1. Postmenstrual age (PMA) appeared to reflect VAN clearance (CL) variability better than gestational age (GA) or postnatal age (PNA) alone. The performance of sigmoid function (Model III) was not superior to the simple exponent function (Model II) with time-varying cWT and PMA, and ADE and BDE models (Model IV and V) seemed ill-conditioning and overparameterized. Therefore, Model II was selected for further analysis due to the lower Akaike information criteria (AIC) and Bayesian information criteria (BIC) compared to other ones. Serum creatinine (SCR), creatinine clearance (CLCR), and co-administration of VAS were recognized as significant covariates on CL. Since SCR and CLCR were apparently correlated with each other and were almost equally-performed, SCR was retained on account of better accessibility in clinic. CL showed a 14% decrease with co-medicating

- VAS. Moreover, cWT was added to volume of distribution (V) for physiologic plausibility (equation 1), and CL was illustrated in equation 2.
- $V = V_{pop} \times \left(\frac{cWT}{1.5}\right) \quad (1)$

108
$$CL = CL_{pop} \times \left(\frac{cWT}{1.5}\right)^{0.75} \times \left(\frac{PMA}{32}\right)^{beta1} \times \left(\frac{30}{SCR}\right)^{beta2} \times F_{VAS} \quad (2)$$

109 Where V is volume of distribution of VAN, V_{pop} is the population estimate of V, cWT is 110 the current body weight, CL is clearance, CL_{pop} is population estimate of CL, PMA is postmenstrual age, SCR is serum creatinine, and F_{VAS} is the scaling factor for co-111 112 medication of VAS. 113 Goodness-of-fit plots for the base model and final model were illustrated in Fig. 2. In 114 contrast to the base model, plot of the final model showed no obvious bias or trend and 115 much improved. The plots of normalized prediction distribution error (NPDE) were 116 presented in Fig. S1. The histogram and probability density plot met the normality well, 117 indicating a good fit of the model to individual data (Fig. S1). In the bootstrap process of 118 2000 time runs, the median parameter estimates were close to the final model (Table S2). 119 99% runs were successful, and bias in fixed effects were less than 5%, indicating that the 120 final model was stable and able to redetermine the estimates of population PK parameters. 121 Twenty-eight patients from Li's study were included for external evaluation of the 122 established model (10). In this data set, all the observations collected were troughs. The 123 medians of cWT, PMA, and SCR were 1.66 kg (range, 0.80 to 2.52 kg), 33.22 weeks (range, 124 28.28 to 36.71 wk), and 35.42 µmol/liter (range, 14.17 to 51.71 µmol/liter) respectively. 125 No patient was co-administered VAS. Mean prediction error (MPE) and mean absolute

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

prediction error (MAPE) of the final model was 3.97% (SD, 19.88%) and 13.01% (SD, 15.36%) respectively. Since the external showed no obvious bias of the established model, we combined all the data and re-estimate the PK parameters. The estimates of the PK parameters did not show an apparent difference (Table 1). **Determination of the PK/PD target** (i) **AKI analysis**. AKI occurrence was screened for all the patients (Fig. 1). Generally, most of patients were not prescribed renal toxic agents besides VAN. VAS was the major nephrotoxin with the prescription for 36 individuals. Other typical renal toxic agents, like furosemide and ibuprofen, were applied for 30 and 8 patients respectively. Seven patients were observed AKI during VAN treatment. Once AKI discovered, VAN dosage adjustments were executed by physicians immediately. Except 2 deaths, renal function of 5 survivals with initial impairment recovered as a lag decrease of SCR within 5 days of therapy. Not unexpectedly, AKI patients had suppressed renal function with abnormally higher SCR, lower CLCR and VAN CL. AUC24 of them were dramatically elevated though there was no statistical difference in daily dose between AKI and non-AKI individuals (Table 2, Fig. 3). Most other characteristics were generally similar. In contrast to non-AKI patients, AKI patients were more likely to be prescribed by MEM, VAS, and furosemide. AKI patients also had a smaller PNA and a higher morbidity of PDA (Table 2).

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

AUC₂₄ was confirmed strongly correlated with AKI in univariate logistic regression (ULR) (P<0.01) (Table 3). AUC₂₄ of 623 (mg·h)/liter was detected as the threshold for AKI of by ROC analysis (Table 3, Fig. 4). This indicated AUC₂₄ was a good predictor for AKI occurrence. PNA, PPHN, and concomitant use of VAS or furosemide were found as potential influence factors of AKI besides AUC₂₄ (Table S3). Significant correlation between AUC₂₄ and C_{min} (trough concentration) was identified (Spearman coefficient = 0.88, P < 0.01). Therefore, C_{min} was not included for further analysis. SCR and CLCR were also excluded because they were diagnostic criteria of AKI. In multivariate logistic regression (MLR), independent predictors of AKI included AUC₂₄ \geq 623 (mg·h)/liter and concomitant use of VAS (Table 4). (ii) Efficacy analysis. Seventy-nine patients had positive blood culture results among the whole population. Thirty-one patients with blood culture proved non-staphylococcal sepsis, 4 patients with polymicrobial infections, and 2 patients co-administered anti-infective sensitive to the identified staphylococcus were excluded. Finally, 42 individuals with blood culture proved staphylococcal sepsis were eligible for efficacy analysis (Fig. 1). Sixteen individuals of them infected by S. aureus, and others by other Staphylococcus spp. Seven patients experienced treatment failure. Three were dead during VAN therapy and 4 were observed with positive blood culture at ≥ 5 days after VAN started. Linezolid (LZD) therapies were then applied as an alternative for them with satisfied clinical outcomes. None with recurrence of bacteremia was observed during their hospital stay. Most patients with ineffective treatment were very-low-birth-weight (VLBW) ones compared to effective patients including both low-birth-weight (LBW) and normal-birth-

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

weight (NBW) individuals. Mortality of ineffective individuals was also higher, while all effective members were survived. Despite insignificant difference in daily dosage and MICs, AUC₂₄/MIC were much lower among ineffective ones. (Table 2, Fig. 3). AUC₂₄/MIC was found marginally significantly correlated with clinical efficacy (P < 0.1) (Table 3). The threshold for efficacy identified by ROC curve was AUC₂₄/MIC of 242 (Table 3, Fig. 4). In ULR, bWT (birth weight) and cWT, two variables highly correlated, seemed strongly associated with efficacy (P < 0.05) (Table S3). cWT was included in MLR since it better reflected the actual physiological status when VAM was applied. Results of MLR revealed that cWT < 1.3 kg and AUC₂₄/MIC < 242 were significant risk factors of treatment failure. Dosing regimen design On the basis of statistical analysis above, VAN PK/PD target in neonates was set as AUC₂₄/MIC of 250 to 600 with MIC assumed to 1 mg/liter. The dosage regimens recommended by current references and this study were displayed in Table 5 and Table 6 respectively (11, 12). According to results in Table 6, patients with concomitant use of VAS were required a reduced daily dose. In general, dosing interval of 18 to 24 h was suitable for extremely preterm patients (PMA < 28 wk) with single dosage of 10 to 20 mg/kg. For preterm ones with PMA of 28 to 36 wk, proper dosing intervals varied from 12 to 18 h. It was enough for term neonates with interval of 8 to 12 h. Interval shorter than 8 h seemed unnecessary.

Our results suggested daily dose of extremely-low-birth-weight (ELBW) neonates with birth weight < 1 kg was 12.5 to 23 mg/kg. However, Neonatal Formulary recommended a daily dose of 20 mg/kg for all ELBW neonates and the maximum daily dose of Red Book for these patients was 30 mg/kg. Quite a number of ELBW neonates were obviously overdosed in these references (Table 5). Table 6 also showed a daily dose of 20 to 52.5 mg/kg was required for NBW neonates with birth weight > 2.7 kg and SCR \leq 60 μ mol/liter. While Red Book claimed a daily dose of 30 mg/kg for patients (GA > 28 wk) with normal renal function (SCR < 61.7 μ mol/liter) (Table 5). It was apparent that this regimen was unable to satisfy the treatment need of large proportional NBW neonates.

DISCUSSION

AUC₂₄/MIC of 400 to 600 has been identified as the recommended PK/PD target in adults while few studies incorporating population PK modeling were conducted to determine or verify PK/PD target for VAN treatment in neonates (2, 3). In our study, a Bayesian-derived target of AUC₂₄/MIC 250 to 600 has been established in neonatal population for the first time and applied to design individualized dosing regimen.

In order to ensure the accuracy of PK parameter estimation, a population PK model has been developed and evaluated. The clearance of a typical patient with cWT of 1.5 kg, PMA of 32 weeks, SCR of 30 μmol/liter, and without VAS co-medication is estimated to 0.06 liter/(h·kg). This value is consistent with the range of 0.04 to 0.10 liter/(h·kg) from previous VAN population PK reports in neonates, and no obvious ethnic difference is observed (10.

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

13-20). The results of external evaluation also confirm that the predictive ability is satisfying. The recommended PK/PD target in adults is determined by AUC₂₄ estimated using validated Bayesian method and MICs obtained by broth microdilution method (BMD) approach (3). Achievement of our target complies with exactly the same method. This allows us to compare these two targets obtained from different populations directly. It is noticed that the lower limit of target for neonates is relatively lower (AUC/MIC of 250 vs. 400) and two target ranges are overlapped in some extent. The threshold in predicting VAN efficacy is obtained on the basis of staphylococcal sepsis in this study, while VAN treatment in neonates with staphylococcal infections is rarely reported to fail (3). It is reasonable that a lower AUC₂₄/MIC ratio target is also possible to be effective for neonates with staphylococcal LOS. Our population PK model has identified VAS as an indicator of decreased VAN CL. The application of VAS for ICU neonates has also been reported as an independent risk factor for development of AKI (21). In our study, 85.7% (6/7) patients with AKI were comediated with VAS. Zhao's study regards VAS as an indirect surrogate for the severity of illness on account of its application often accompanied by decreased blood pressure and hypoperfusion (22). AKI may be induced in such a pathophysiological condition. Whether VAN has a direct renal toxic effect or whether high exposure is a consequence of renal impairment is still under debate (23). Previous report illustrates that VAN-induced nephrotoxicity does not exist alone but occurs when other nephrotoxins are coadministered (6, 23), and the major nephrotoxin in our institution is VAS. Results of MLR

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

shows high VAN exposure of AUC₂₄ \geq 623 (mg·h)/liter remains an independent predictor of AKI after adjustment of concomitant use of VAS. Although our study cannot explain whether the threshold for AKI will be varied by concomitant use of VAS, there is a reason to believe both high VAN exposure and VAS application probably co-contribute the development of AKI. Seven (4%) cases of VAN-induced AKI were observed in this study within the range of 1 to 9% as former report (24). Except 2 deaths, renal functions of survivals were recovered to normal level with the progress of treatment although VAN exposures were abnormally high in a short period. The VAN dosage of them was kept monitoring and adjusted based on TDM results. All survivals were recovered without other obvious ADRs during their hospital stay. This finding agrees with the previous report in children (25). It indicates that neonates may be relatively tolerant to high VAN exposure and renal impairments for them are reversible. The ongoing monitoring of both VAN concentrations and SCR needs to be emphasized during the treatment to ensure the discovery of AKI without delay and avoid possible serious ADRs. In the efficacy analysis, when adjusted by cWT < 1.3 kg, a clear association between AUC₂₄/MIC < 242 and VAN treatment failure has been verified. Low-weight neonates, especially individual weighted less than 1.5 kg, often means growth defects, higher mortality and more morbidities (26). It is reasonable that low-weight neonates are more likely to experience treatment failures. The relationship between VAN exposure and clinical efficacy failed to establish in past pediatric and neonatal studies (8, 27). The possible reasons for this disparity may be caused

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

by following points. Primarily, previous studies contain patients with various infection sites while all patients in our study have bloodstream infection (8, 27). Considering several breakpoints reported by studies on different infectious diseases in adults, the threshold of AUC/MIC may be varied by different infection sites (28-30). Secondly, the whole population in previous studies are under a relatively low VAN exposure (8, 27). The correlation between efficacy and AUC₂₄/MIC ratio may not possible to be established due to AUC₂₄/MIC ratios concentrated within a narrow range. The comparison of characteristics of effective and ineffective patients reflects that main reason for treatment failure is still inadequate VAN exposure (AUC₂₄). In contrast to our study, regimens in current references seems over-simplified. The scheme in Neonatal Formulary is merely PMA-based while regimen in Red Book is designed on the basis of GA and SCR (11, 12). According to our population PK model, renal function and concomitant use of VAS are significant covariates on VAN CL and unable to be out of consideration in regimen design. GA alone is not enough to describe the maturation of neonates and PMA is a better predictor for CL apparently. Overall, the current recommended regimens from Neonatal Formulary and Red Book are inappropriate and regimen designed in this study seemed more sophisticated and suitable for clinical practice. There are several limitations in our study. First, PK/PD target found in this study gives no consideration of bacterial resistance which needs the support of further microbiological researches. Second, the sample size for the study is small especially for patients with AKI or ineffective treatment. Although this did not affect our ability to find statistical breakpoints in predicting AKI or VAN treatment failure, it is not a sufficiently robust

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

sample to support the established PK/PD target. Last but not the least, the retrospective nature of this study may lead to confounding and bias that may well be avoided with prospective study methods. Our findings need to be validated further in large multicentered prospective studies. **CONCLUSION** In conclusion, AUC₂₄/MIC is a good predictor for VAN toxicity and efficacy in neonates. A Bayesian-derived AUC₂₄/MIC ratio of 250 to 600 is regarded as an appropriate PK/PD target of VAN treatment assumed MIC to 1 in ICU neonates balancing treatment achievement and AKI risks. AKI is more likely to occur when VAN is applied with concomitant use of VAS. Underdose of VAN and low-weight of neonates co-contribute to possible treatment failure. Individualized dosing regimens on the basis of the developed target are valuable for clinical practice. **METHODS** Study design A single center retrospective observational cohort study was conducted at Nanjing Maternity and Child Health Care Hospital (Nanjing, China). The electronic medical records of all patients who accepted VAN therapy in NICU from 1st January 2016 to 31st December 2019 were reviewed to determine eligibility.

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

This study was executed in accordance with the recommendations of the Declaration of Helsinki (2000). The protocol was approved by the Ethics Committee of Nanjing Maternity and Child Health Care Hospital. Identities of patients were hidden during the study. Informed consent was approved unnecessary due to retrospective nature of the study. This study was registered at chictr.org.cn under identifier ChiCTR1900027919. **Study population** Patients with postmenstrual age (PMA) \leq 48 weeks when VAN began were included. All individuals were treated with VAN for at least three days and at least one serum concentration was monitored. The exclusion criteria were as follows: Complete data were unavailable; VAN serum concentrations were out of the calibration range of analytical devices. Information of interest included: GA, PNA, PMA, bWT, cWT, dosing history, VAN serum concentration, SCR, CLCR calculated by Schwartz equation (31), co-medications (especially concomitant use of nephrotoxins like VAS, non-steroidal anti-inflammatory drugs, or loop diuretics), clinical diagnosis, radiographic examinations, laboratory tests and microbiology culture. According to the local protocol, neonates with suspected or confirmed sepsis received empirical therapy with VAN in combination with MEM based on presumptive diagnosis. Once a diagnosis was established, anti-infectives were rationalized to cover the causative pathogen. Target trough levels of VAN according to local guidelines were 10 to 20 mg/liter (32). As this was an observational and respective study, dosage adjustment based on TDM results were determined at the discretion of treating physicians.

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

VAN (Vancocin, Lilly, S.A, Suzhou, China) was administered 10~15 mg/kg per time from every 8 to 18 h with intermittent infusion lasting 60 min. Blood samples were monitored half an hour before the start of vancomycin (trough concentration) or half an hour after the completion of infusion (peak concentration). All the samples were collected prior to the fourth or fifth dose (steady state). If the dosage was changed, it recommended TDM until steady state was reached. **Analytical method** VAN concentrations were analyzed by fluorescence polarization immunoassay with an ARCHITECT i2000SR (Abbott Laboratories, Chicago, IL, USA) within 24 h after samples obtained. The limit of detection was 1 mg/liter, and the calibration range of this assay was 3 to 100 mg/liter. The intra-day and inter-day coefficients of variation (CV) were less than 20%. Any concentration out of calibration range were excluded from the study. SCR samples were analyzed with enzymatic method by using Beckman Coulter AU5800 (Beckman Coulter Inc., Brea CA, USA). The calibration range was from 3 to 100 mg/liter. The intra-day and inter-day CVs were less than 3.75%. Etiological examinations were provided by clinical laboratory of our hospital by using VITEK 2 microbial identification system (bioMérieux, Lyon, France). BMD method was used to determine MICs. The interpretative reports were issued by the laboratory technicians according to the criteria recommended by the Clinical Laboratory Standards Institute (CLSI). **Population PK modeling**

A population PK model was conducted among all individuals in this study to calculate PK

parameters precisely by using Monolix (version 2019R2, Lixoft, France). Stochastic

Approximation Expectation Maximization (SAEM) algorithm was used to estimate PK

341 parameters and their variability.

338

339

- One or two compartment model with first-order elimination was tried to fit the dataset.
- 343 The interindividual variability of the pharmacokinetic parameters was estimated by using
- an exponential model and was expressed as equation 3:

$$P_i = P_{pop} \times e^{\eta_i} \quad (3)$$

- where P_{pop} is the population typical value of parameter, and P_i refers to parameter value of
- the ith subject with random variable η_i , which is assumed normally distributed with a mean
- 348 of zero and variance of ω^2 .
- Residual unexplained variability was tested by an additive model, exponential model, or a
- 350 combined additive and exponential model.
- 351 The potential covariates were investigated for their influence on PK parameters.
- 352 Considering the rapid changing pathophysiological status of neonates, all the covariates
- were defined as time-varying ones (regressor in Monolix). Any categorical variable present
- in less than 20% of the population was not going to be tested.
- 355 Five models were employed to describe the impacts of size (weight) and maturation (age)
- on VAN CL (33). The performance of model fitting was investigated in further analysis.
- 357 Model I ~ III based on weight scaling of CL were tested using equation 4.

358
$$CL_i = CL_{pop} \times \left(\frac{WT}{WT_{median}}\right)^{k_1} \times MF \quad (4)$$

- where CL_i is the typical clearance of ith individual, and CL_{pop} is population typical value of
- 360 VAN clearance. WT is the weight of ith individual and WT_{median} is median weight of the
- population. k_1 is the exponent. MF represents the maturation factor (MF) which defines the
- maturing process. It is set to 1 for all the models except Model III.
- 363 *Model I*: in the base model, the exponent k_1 is fixed to 0.75 (34).
- 364 *Model II*: in the simple exponent model, the exponent k_1 is fixed to 0.75. Age (GA, PNA,
- and PMA) with exponential function is tested to explore the effect on VAN CL.
- 366 *Model III*: in the sigmoid maturation model, the exponent k_1 is fixed to 0.75 and MF is
- 367 calculated according to equation 5 (34).

$$MF = \frac{1}{1 + \left(\frac{Age}{MT_{50}}\right)^{\gamma}} \tag{5}$$

- where MT₅₀ is the value of age when maturation reaches 50 % of the adult clearance, and
- 370 γ is the Hill coefficient which controls the slope of sigmoid function.
- 371 *Model IV*: the ADE model (equation 6) (9).

372
$$k_1 = k_0 - \frac{k_{max} \times Age^{\gamma}}{k_{50}^{\gamma} + Age^{\gamma}}$$
 (6)

373 Model V: the BDE model (equation 7) (35).

$$k_1 = k_0 - \frac{k_{max} \times WT^{\gamma}}{k_{50}^{\gamma} + WT^{\gamma}}$$
 (7)

- where k_0 is the value of the exponent at birth (0 years) (Model IV) or at a theoretical weight
- of zero (Model V), k_{max} is the maximum decrease of the exponent, k₅₀ is the age (Model

IV) or weight (Model V) at which a 50 % decrease in the maximum decrease is attained, and γ is the Hill coefficient used to determine the steepness of the sigmoid decline.

Structural models were regarded preferential due to lower AIC and BIC (36). The selection of covariates was determined using a forward selection process and a backward elimination

process. Nested covariate models were statistically compared using a likelihood ratio test

on the differences in the objective function value (OFV). A reduction in OFV of 3.84 (p <

0.05) for forward inclusion and an increase in OFV of 6.63 (p < 0.01) for backward

elimination were the criteria for retaining a covariate in the model.

Both internal validation and external validation were performed to verify the predictive performance of the model. The final model was internally assessed by visual inspection of goodness-of-fit plots, normalized prediction distribution error (NPDE) and bootstrap (36-38). The NPDE distribution was expected to follow a normal distribution with a mean of 0 and a variance of 1. The bootstrap procedure was replicated 2000 runs with the R package Rsmlx (version 2.0.2, https://cran.r-project.org/web/packages/Rsmlx/index.html). The median values and 95% confidence intervals of PK parameters were compared with estimates from the final model. Bias in fixed effects less than 5% was thought acceptable. Bias (%) was calculated by equation 8:

394
$$Bias (\%) = \frac{Bootsrap \ median-final \ model \ estimate}{final \ model \ estimate} \times 100\% \quad (8)$$

The external data set of neonates from Li's research was used to validate the final model (10). MAPE and MPE were applied to calculate bias and imprecision of predictive performance (equation 9 and 10) (39). MAPE and MPE values within the range of 30% and 20% respectively were considered acceptable for the final model.

399
$$MAPE(\%) = \frac{1}{N} \sum \left| \frac{IPRED_i - OBS_i}{OBS_i} \right| \quad (9)$$

$$MPE(\%) = \frac{1}{N} \sum_{i} \frac{IPRED_i - OBS_i}{OBS_i}$$
 (10)

- 401 where IPRED_i and OBS_i is individual prediction and the observation of the ith subject, and
- N is the number of subjects in the data set for external evaluation.

Determination of the PK/PD target

- 404 (i) AKI analysis. AKI occurrence of all the patients were screened. The association
- 405 between VAN exposure and AKI occurrence was investigated and the breakpoint in
- 406 predicting AKI was tried to discover as the upper limit of VAN exposure. AKI definition
- 407 for neonates were: an increase of SCR by 26.5 μmol/liter within 48 h, or a SCR rise to ≥
- 408 1.5 times from the baseline within 7 days, or a urine volume <0.5 ml/(kg·h) for 6 hours
- 409 (40). AUC₂₄ was calculated by equation 11.

$$AUC_{24} = \frac{Daily\ dose}{CL} \quad (11)$$

- Where AUC₂₄ is the Bayesian-derived area-under-the-curve from 0 to 24 h, and CL is VAN
- 412 clearance.

- 413 (ii) Efficacy analysis. Patients with blood culture proved staphylococcal sepsis were
- assessed the qualification of efficacy analysis. Patients with the following characteristics
- were excluded: length of VAN treatment less than 5 days, polymicrobial infection or
- 416 concomitant antimicrobial agent sensitive to the identified staphylococcus.
- 417 The clinical efficacy of eligible patients was analyzed. The correlation between VAN
- 418 steady exposure after dose adjustment and clinical efficacy was explored as well. The

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

breakpoint that provided the greatest difference in treatment failure was regarded as the lower limit of VAN exposure. VAN treatment failure was defined as positive blood culture at ≥ 5 days after initiation of vancomycin treatment, recurrence of bacteremia within 30 days, or 30-day mortality (29, 30, 41). Dosing regimen design The PK model-based dosing recommendations were designed by using the optimal exposure target and were compared with current regimens in Neonatal Formulary and Red Book (11, 12). Virtual patients with different physiological characteristics (i.e., different levels of ages, weights, or renal functions) were set for simulations. The PMA range of virtual patients was designated from 25 to 46 weeks. Their corresponding weights were medians obtained from the Fenton growth chart for neonates (42). 1000 replicates of each scenario were simulated by MC method to detect the most proper dosing scheme (43). R package mlxR (version 4.1.0, https://cran.r-project.org/web/packages/mlxR/index.html) was used to complete this procedure. **Statistical analysis** Baseline characteristics and PK/PD parameters of patients were summarized. Continuous variables were compared in Wilcoxon tests, and dichotomous variables in Fisher exact tests. Threshold values of VAN exposure in predicting AKI or efficacy were identified from Youden index (J) based on the receiver operating characteristic (ROC) analysis. J = maximum (sensitivity + specificity - 1) (44).

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

ULR analyses were performed to test the correlation between variables and AKI occurrence or treatment failure. Potentially significant variables identified by ULR (P< 0.2) were included into MLR to identify predictors for AKI or efficacy (45). If variables were correlated, only one was included into the analysis. For variables exerting significant effects on AKI or efficacy, ROC analysis was employed to find cut-off values to create dichotomous variables for better professional explanation (46). All statistical analyses were executed by R. P < 0.05 was considered as statistically significant. pROC package was used for ROC analysis (version 1.15.3, https://cran.rproject.org/web/packages/pROC/index.html). **DATA AVAILABILITY** The data of this study will be open to public through public access of ResMan (http://www.medresman.org.cn/pub/cn/proj/projectshshow.aspx?proj=1448) within 6 months after publication. ACKNOWLEDGEMENTS The authors would like to thank Dr Xiao-jun Ji (Nanjing Chia Tai Tianging Pharmaceutical Co., Ltd., Nanjing, China) for his assistance with figure plotting. **FUNDING**

This project was partly supported by the National Science Foundation for Young Scientists of China (No.) and Hospital Pharmacy Foundation of Nanjing Pharmaceutical Association (No. 2019YX004). **CONFLICTS OF INTEREST** All authors declare no conflicts of interest.

REFERENCES

479

500

480 1. Jacqz-Aigrain E, Zhao W, Sharland M, van den Anker JN. 2013. Use of 481 antibacterial agents in the neonate: 50 years of experience with vancomycin 482 administration. Semin Fetal Neonatal Med 18:28-34. 483 2. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Jr., Craig W, Billeter M, 484 Dalovisio JR, Levine DP. 2009. Therapeutic monitoring of vancomycin in adult 485 patients: a consensus review of the American Society of Health-System 486 Pharmacists, the Infectious Diseases Society of America, and the Society of 487 Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82-98. 488 3. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, 489 Wong-Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro BM. 2020. 490 Therapeutic monitoring of vancomycin for serious methicillin-resistant 491 Staphylococcus aureus infections: A revised consensus guideline and review by the 492 American Society of Health-System Pharmacists, the Infectious Diseases Society 493 of America, the Pediatric Infectious Diseases Society, and the Society of Infectious 494 Diseases Pharmacists. Am J Health Syst Pharm doi:10.1093/ajhp/zxaa036. 495 4. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. 2011. 496 Vancomycin: we can't get there from here. Clin Infect Dis 52:969-974. 497 5. Matsumoto K, Takesue Y, Ohmagari N, Mochizuki T, Mikamo H, Seki M, 498 Takakura S, Tokimatsu I, Takahashi Y, Kasahara K, Okada K, Igarashi M, Kobayashi M, Hamada Y, Kimura M, Nishi Y, Tanigawara Y, Kimura T. 2013. 499

Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus

- 501 review of the Japanese Society of Chemotherapy and the Japanese Society of 502 Therapeutic Drug Monitoring. Journal of Infection and Chemotherapy 19:365-380. Le J, Ny P, Capparelli E, Lane J, Ngu B, Muus R, Romanowski G, Vo T, Bradley 503 6. 504 J. 2015. Pharmacodynamic Characteristics of Nephrotoxicity Associated With 505 Vancomycin Use in Children. J Pediatric Infect Dis Soc 4:e109-e116. 506 7. Dao K, Guidi M, Andre P, Giannoni E, Basterrechea S, Zhao W, Fuchs A, Pfister 507 M, Buclin T, Csajka C. 2019. Optimisation of vancomycin exposure in neonates evidence. 508 based the best level of Pharmacol Res on 509 doi:10.1016/j.phrs.2019.104278:104278. 510 8. Hahn A, Frenck RW, Allen-Staat M, Zou Y, Vinks AA. 2015. Evaluation of Target 511 Attainment of Vancomycin Area Under the Curve in Children With Methicillin-512 Resistant Staphylococcus Aureus Bacteremia. Ther Drug Monit 37:619-625. 513 9. Ding J, Wang Y, Lin W, Wang C, Zhao L, Li X, Zhao Z, Miao L, Jiao Z. 2014. A 514 Population Pharmacokinetic Model of Valproic Acid in Pediatric Patients with 515 Epilepsy: A Non-Linear Pharmacokinetic Model Based on Protein-Binding Saturation. Clin Pharmacokinet 54:305-317. 516 517 10. Li JJ, Liu YX, Tang L, Weng XH, Wang SN, Jiao Z, Shang EN. 2017. Population
- Mills Q. 2014. Neonatal Formulary 7: Drug Use in Pregnancy and the First Year of
 Life, 7 ed. Wiley Blackwell. BMJ., UK.

Pharmacokinetics of Vancomycin in Chinese Neonates. Chin Pharm J 52:1434-

518

519

1441.

- 522 12. Pediatrics AAo, in Kimberlin DW, Brady MT, Jackson MA, (ed) LS. 2018. Red
- Book: Report of the Committee on Infectious Diseases, 31 ed. Itasca, IL: American
- Academy of Pediatrics, USA.
- 525 13. Seay RE, Brundage RC, Jensen PD, Schilling CG, Edgren BE. 1994. Population
- 526 pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther 56:169-175.
- 527 14. Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K. 2004.
- Population pharmacokinetics of arbekacin, vancomycin, and panipenem in
- neonates. Antimicrob Agents Chemother 48:1159-1167.
- 530 15. Anderson BJ, Allegaert K, Van den Anker JN, Cossey V, Holford NHG. 2007.
- Vancomycin pharmacokinetics in preterm neonates and the prediction of adult
- clearance. Br J Clin Pharmacol 63:75-84.
- 533 16. Lo YL, van Hasselt JG, Heng SC, Lim CT, Lee TC, Charles BG. 2010. Population
- pharmacokinetics of vancomycin in premature Malaysian neonates: identification
- of predictors for dosing determination. Antimicrob Agents Chemother 54:2626-
- 536 2632.
- 537 17. Marques-Minana MR, Saadeddin A, Peris JE. 2010. Population pharmacokinetic
- analysis of vancomycin in neonates. A new proposal of initial dosage guideline. Br
- 539 J Clin Pharmacol 70:713-720.
- 540 18. Oudin C, Vialet R, Boulamery A, Martin C, Simon N. 2011. Vancomycin
- prescription in neonates and young infants: toward a simplified dosage. Arch Dis
- 542 Child Fetal Neonatal Ed 96:F365-370.

- 543 19. Zhao W, Lopez E, Biran V, Durrmeyer X, Fakhoury M, Jacqz-Aigrain E. 2012.
- Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic
- drug monitoring. Arch Dis Child 98:449-453.
- 546 20. Li ZL, Liu YX, Jiao Z, Qiu G, Huang JQ, Xiao YB, Wu SJ, Wang CY, Hu WJ, Sun
- HJ. 2018. Population Pharmacokinetics of Vancomycin in Chinese ICU Neonates:
- Initial Dosage Recommendations. Front Pharmacol 9:603.
- 549 21. Stojanovic V, Barisic N, Milanovic B, Doronjski A. 2014. Acute kidney injury in
- preterm infants admitted to a neonatal intensive care unit. Pediatr Nephrol 29:2213-
- 551 20.
- 552 22. Zhao W, Hill H, Le Guellec C, Neal T, Mahoney S, Paulus S, Castellan C, Kassai
- B, van den Anker JN, Kearns GL, Turner MA, Jacqz-Aigrain E, Consortium T.
- 554 2014. Population pharmacokinetics of ciprofloxacin in neonates and young infants
- less than three months of age. Antimicrob Agents Chemother 58:6572-6580.
- 556 23. Chavada R, Ghosh N, Sandaradura I, Maley M, Van Hal SJ. 2017. Establishment
- of an AUC 0–24 Threshold for Nephrotoxicity Is a Step towards Individualized
- Vancomycin Dosing for Methicillin-Resistant Staphylococcus aureus Bacteremia.
- Antimicrob Agents Chemother 61.
- Lestner JM, Hill LF, Heath PT, Sharland M. 2016. Vancomycin toxicity in neonates:
- a review of the evidence. Curr Opin Infect Dis 29:237-247.
- 562 25. Le J, Vaida F, Nguyen E, Adler-Shohet FC, Romanowski G, Kim J, Vo T,
- 563 Capparelli EV. 2014. Population-Based Pharmacokinetic Modeling of Vancomycin
- in Children with Renal Insufficiency. J Pharmacol Clin Toxicol 2:1017-1026.

- 565 26. A. GC, E. JS. 2018. Avery's Diseases of the Newborn, 10 ed. Elsevier Inc,
- 566 Philadelphia, PA.
- 567 27. Padari H, Oselin K, Tasa T, Metsvaht T, Loivukene K, Lutsar I. 2016. Coagulase
- negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose
- or target? BMC Pediatr 16:206.
- 570 28. Gawronski KM, Goff DA, Jack B, Khadem TM, Bauer KA. 2013. A Stewardship
- Program's Retrospective Evaluation of Vancomycin AUC24/MIC and Time to
- 572 Microbiological Clearance in Patients with Methicillin-Resistant Staphylococcus
- aureus Bacteremia and Osteomyelitis. Clinical Therapeutics 35:772-779.
- 574 29. Jung Y, Song KH, Cho J, Kim HS, Kim NH, Kim TS, Choe PG, Chung JY, Park
- 575 WB, Bang JH, Kim ES, Park KU, Park SW, Kim HB, Kim NJ, Oh MD. 2014. Area
- under the concentration-time curve to minimum inhibitory concentration ratio as a
- 577 predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus
- 578 aureus bacteraemia. Int J Antimicrob Agents 43:179-183.
- 579 30. Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, Rybak MJ.
- 580 2015. Association between vancomycin day 1 exposure profile and outcomes
- among patients with methicillin-resistant Staphylococcus aureus infective
- endocarditis. Antimicrob Agents Chemother 59:2978-2985.
- 583 31. Schwartz GJ, Brion LP, Spitzer A. 1987. The Use of Plasma Creatinine
- Concentration for Estimating Glomerular Filtration Rate in Infants, Children, and
- Adolescents. Pediatric Clinics of North America 34:571-590.
- 586 32. Ye Z-K, Chen Y-L, Chen K, Zhang X-L, Du G-H, He B, Li D-K, Liu Y-N, Yang
- 587 K-H, Zhang Y-Y, Zhai S-D. 2016. Therapeutic drug monitoring of vancomycin: a

588 guideline of the Division of Therapeutic Drug Monitoring, Chinese 589 Pharmacological Society. Journal of Antimicrobial Chemotherapy 71:3020-3025. 590 33. Jacqz-Aigrain E, Leroux S, Zhao W, van den Anker JN, Sharland M. 2015. How to 591 use vancomycin optimally in neonates: remaining questions. Expert Rev Clin 592 Pharmacol 8:635-648. 593 34. Holford N, Heo YA, Anderson B. 2013. A pharmacokinetic standard for babies and 594 adults. J Pharm Sci 102:2941-2952. 595 35. Wang C, Peeters MY, Allegaert K, Blusse van Oud-Alblas HJ, Krekels EH, Tibboel 596 D, Danhof M, Knibbe CA. 2012. A bodyweight-dependent allometric exponent for 597 scaling clearance across the human life-span. Pharm Res 29:1570-1581. 598 Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dai H, Dong J, Ruiz-Garcia 36. 599 A, Sweeney K, Cronenberger C. 2013. Establishing Best Practices and Guidance in 600 Population Modeling: An Experience With an Internal Population Pharmacokinetic 601 Analysis Guidance. CPT Pharmacometrics Syst Pharmacol 2:e51. 602 Ette EI. 1997. Stability and performance of a population pharmacokinetic model. J 37. 603 Clin Pharmacol 37:486-495. 604 38. Comets E, Brendel K, Mentré F. 2008. Computing normalised prediction 605 distribution errors to evaluate nonlinear mixed-effect models: The npde add-on 606 package for R. Comput Methods Programs Biomed 90:154-166. 607 39. van der Meer AF MM, Touw DJ, Proost JH, Neef C. 2011. Optimal Sampling 608 Strategy Development Methodology Using Maximum A Posteriori Bayesian

Estimation. Ther Drug Monit 33:133-146.

- 610 40. Khwaja A. 2012. KDIGO clinical practice guidelines for acute kidney injury.
- Nephron Clin Pract 120:c179-184.
- 612 41. Al-Sulaiti FK, Nader AM, Saad MO, Shaukat A, Parakadayathu R, Elzubair A, Al-
- Badriyeh D, Elewa H, Awaisu A. 2019. Clinical and Pharmacokinetic Outcomes of
- Peak-Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug
- Monitoring Approaches: A Pragmatic Randomized Controlled Trial. Eur J Drug
- Metab Pharmacokinet 44:639-652.
- 617 42. Fenton TR, Sauve RS. 2007. Using the LMS method to calculate z-scores for the
- Fenton preterm infant growth chart. Eur J Clin Nutr 61:1380-5.
- 619 43. Trang M, Dudley MN, Bhavnani SM. 2017. Use of Monte Carlo simulation and
- 620 considerations for PK-PD targets to support antibacterial dose selection. Curr Opin
- 621 Pharmacol 36:107-113.
- 622 44. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M. 2011.
- 623 pROC: an open-source package for R and S+ to analyze and compare ROC curves.
- BMC Bioinformatics 12:77.
- 625 45. Zhang Z. 2016. Model building strategy for logistic regression: purposeful selection.
- 626 Ann Transl Med 4:111.
- 627 46. Zhou ZR, Wang WW, Li Y, Jin KR, Wang XY, Wang ZW, Chen YS, Wang SJ,
- Hu J, Zhang HN, Huang P, Zhao GZ, Chen XX, Li B, Zhang TS. 2019. In-depth
- mining of clinical data: the construction of clinical prediction model with R. Ann
- 630 Transl Med 7:796.

FIGURES

633




FIG 1 Study flow

634




FIG 2 Goodness-of-fit plot.

(A) Population predictions vs. observations. (B) Individual predictions (IPRED) vs. observations. (C) The time vs. the individual weighted residual errors (IWRES). (D) Serum concentrations (Cc) vs. IWRES. The black solid lines are the reference lines, and yellow solid lines are the loess smooth lines.




FIG 3 Boxplots of VAN exposure parameters.

(A) Boxplot of AUC₂₄ and occurrence of AKI. (B) Boxplot of AUC₂₄/MIC and VAN efficacy. Bold lines mean medians and fine lines shows lower and upper quartiles. Black color stands for AKI patients and red color for non-AKI ones. Orange color represents effective individuals and blue color represents ineffective ones.




FIG 4 ROC analysis.

(A) ROC curve in AKI analysis (B) ROC curve in efficacy analysis. AUC is area under the curve.

666 TABLES

667

668

669

670

671

TABLE 1 Results of population PK modeling

Parameter ^a	Origi	Original data set		data set ^c
	Value	RSE (%) ^b	Value	RSE (%)
Fixed Effects				
V _{pop} , liter	0.86	3.02	0.86	3.85
CL _{pop} , liter/h	0.09	2.11	0.09	2.10
beta1	2.35	1.20	2.40	3.03
beta2	0.18	3.41	0.22	2.86
F_{VAS}	0.86	0.34	0.86	0.30
Standard Deviation of the Random Effects				
omega_V	0.11	24.20	0.15	21.40
omega_CL	0.24	6.85	0.23	6.79
Error Model Parameters				
b	0.21	4.82	0.21	5.04

VAN clearance; F_{VAS}. scaling factor of VAS co-medication; omega_V, standard deviation of random effects for volume of distribution; omega_CL, standard deviation of random

^aV_{pop}, population typical value of volume of distribution; Cl_{pop}, population typical value of

effects for VAN clearance; b, residual error parameter.

bRSE, relative standard error.

673 ^cA new data set combines original data set and the data set of external validation.

TABLE 2 Baseline demographic characteristics and PK parameters in AKI analysis and efficacy analysis.

	AKI analysis ^b			Efficacy analysis		
	Normal patients	AKI patients		Effective patients	Ineffective patients	
Variable ^a	(N=175)	(N=7)	P	(N=35)	(N=7)	P
	median	median	1	median	median	1
	(range/proportion)	(range/proportion)		(range/proportion)	(range/proportion)	
Maturation						
Gender	98/77 (male/female)	4/3 (male/female)	1.00	18/17 (male/female)	5/2 (male/female)	0.43
GA, wk	30.43 (22.29~41.29)	33.86 (24.71~40.00)	0.20	31.00 (24.43~40.00)	29.71 (26.29~33.29)	0.32
PNA, wk	2.24 (0.28~12.62)	0.85 (0.57~3.71)	< 0.05	2.57 (0.93~5.00)	2.57 (0.85~4.43)	1.00
PMA, wk	33.33 (22.60~46.25)	34.78 (28.29~40.71)	0.48	33.81 (26.50~41.04)	32.28 (27.00~35.28)	0.32
bWT, kg	1.35 (0.55~4.40)	1.74 (0.77~3.05)	0.43	1.37 (0.70~3.03)	0.95 (0.77~1.18)	< 0.01
cWT, kg	1.58 (0.57~5.63)	1.80 (1.20~3.02)	0.57	1.58 (0.78~3.05)	1.25 (0.76~1.56)	< 0.01
Renal Function						
SCR, µmol/liter	26.70 (3.90~77.50)	85.90 (22.10~107.10)	< 0.01	24.60 (9.60~55.21)	22.80 (10.70~44.40)	0.79
CLCR, (ml/min)/1.73m ²	35.33 (9.69~142.18)	19.73 (9.09~39.51)	< 0.01	37.40 (17.55~81.95)	36.71 (22.37~51.40)	0.60
PK Parameters						
Daily dose, mg/kg	30.00 (13.33~63.22)	28.80 (19.35~46.69)	0.33	29.11 (15.48~44.26)	28.32 (18.42~58.97)	0.38
CL, liter/(h·kg)	0.06 (0.02~0.16)	0.03 (0.03~0.05)	< 0.01	$0.06 (0.04 \sim 0.16)$	$0.06 (0.05 \sim 0.12)$	0.97
C _{min} , mg/liter	12.38 (3.11~33.01)	23.10 (12.51~51.36)	< 0.01	13.48 (3.39~18.96)	11.38 (7.50~12.76)	< 0.05
AUC ₂₄ , (mg·h)/liter	468.70 (203.30~1118.40)	772.00 (476.90~1385.80)	< 0.01	471.60 (272.10~627.80)	440.90 (325.60~485.10)	< 0.1
MIC, mg/liter	/	/	/	2.0 (0.5~2.0)	2.0 (2.0~2.0)	0.12

AUC ₂₄ /MIC	/	/	/	256.40 (136.00~1030.30)	215.60 (162.80~242.50)	< 0.01
Comorbidities						
PDA	74 (42.3%)	7 (100.0%)	< 0.01	10 (28.6%)	3 (42.9%)	0.66
Pneumonia	74 (42.3%)	4 (57.1%)	0.46	8 (22.9%)	3 (42.9%)	0.35
BDP	41 (23.4%)	2 (28.6%)	0.67	5 (14.3%)	2 (28.6%)	0.27
Meningitis	36 (20.6%)	1 (14.3%)	1.00	4 (11.4%)	0 (0.00%)	1.00
NEC	31 (17.7%)	2 (28.6%)	0.61	5 (14.3%)	0 (0.00%)	0.57
PPHN	14 (8.00%)	2 (28.6%)	0.12	2 (5.71%)	0 (0.00%)	1.00
Co-medication						
Meropenem	82 (46.9%)	7 (100.0%)	< 0.01	11 (31.4%)	2 (28.6%)	1.00
VAS	30 (17.1%)	6 (85.7%)	< 0.01	2 (5.71%)	1 (14.3%)	0.43
Furosemide	26 (14.9%)	4 (57.1%)	< 0.05	1 (2.86%)	1 (14.3%)	0.31
Ibuprofen	8 (4.57%)	0 (0.00%)	1.00	1 (2.86%)	0 (0.00%)	1.00
Outcome						
Mortality	13 (7.43%)	2 (28.6%)	0.10	0 (0.00%)	3 (42.9%)	< 0.01

^aGA, gestational age; PNA, postnatal age; PMA, postmenstrual age; bWT, birth weight; cWT, current body weight; SCR, serum creatinine; CLCR, creatinine clearance; CL, VAN clearance; Cmin, trough concentration; PDA, patent ductus arteriosus; BDP, bronchopulmonary dysplasia; NEC, neonatal necrotic enterocolitis; PPHN, persistent pulmonary hypertension of newborn; VAS, vasoactive drugs, which are referred to milrinone, dopamine, epinephrine, and norepinephrine in our institution.

^bAKI, acute kidney injury.

TABLE 3 Results of ULR and ROC analysis

	OR (P) ^b	AUCroc (95% CI) ^c	Cut-off	SP ^d	SE ^e
AKI analysis					
AUC24, (mg·h)/liter	1.01 (<0.01)	0.89 (0.77~1.00)	623	0.85	0.86
Efficacy analysis					
AUC ₂₄ /MIC	1.02 (<0.1)	0.81 (0.67~0.95)	242	0.86	0.66

^aAKI, acute kidney injury.

^bOR, Odds ratio and corresponding P value for univariate logistic regression.

^cAUC_{ROC}, area under curve for ROC curve.

^dSP, specificity of ROC analysis.

^eSE, sensitivity of ROC analysis.

TABLE 4 Results of MRL

Variable ^a	OR ^a (95%CI)	P
AKI analysis		
AUC ₂₄ ≥623 (mg·h)/liter	31.15 (3.21~302.00)	< 0.01
Concomitant use of VAS	28.67 (2.95~278.52)	< 0.01
Efficacy analysis		
$AUC_{24}/MIC < 242$	0.09 (0.01~0.97)	< 0.05
cWT<1.3kg	0.11 (0.01~0.80)	< 0.05

^aAKI, acute kidney injury.

^bOR, adjusted odds ratio.

TABLE 5 Dose recommendations in current references

Reference	Age (wk) / SCR (µmol/liter) ^a	Dose recommendations ^b
Neonatal Formulary	PMA <29	20mg/kg,q24h
	PMA 30~33	20mg/kg,q18h
	PMA 34~37	20mg/kg,q12h
	PMA 38~44	15mg/kg,q8h
	PMA > 45	10mg/kg,q6h
Red Book	GA≤28	LD: 20mg/kg
	SCR <44.2	MD: 15mg/kg,q12h
	SCR 44.2~61.7	MD: 20mg/kg,q24h
	SCR 70.6~88.2	MD: 15mg/kg,q24h
	SCR 97.0~123.5	MD: 10mg/kg,q24h
	SCR >123.5	MD: 15mg/kg,q48h
	GA > 28	LD: 20mg/kg
	SCR <61.7	MD: 15mg/kg,q12h
	SCR 61.7~79.4	MD: 20mg/kg,q24h
	SCR 88.2~105.8	MD: 15mg/kg,q24h
	SCR 114.7~141.2	MD: 10mg/kg,q24h
	SCR >141.2	MD: 15mg/kg,q48h

^{713 &}lt;sup>a</sup>SCR, serum creatinine; PMA, postmenstrual age; GA, gestational age.

⁷¹⁴ bLD, loading dose; MD, maintenance dose.

TABLE 6 Results of dosing regimen simulation

cWT ^a	PMA ^b	SCR ^c	D. C. A. M. A. T. A. G. d.	D () A MARIAG
(kg)	(wk)	(µmol/liter)	Patients without VAS ^d	Patients with VAS
0.7~0.99	25~27	10	15~17.5mg/kg, q18h	17.5~20mg/kg,q24h
		25	12.5~15mg/kg, q18h	15~17.5mg/kg, q24h
		45	12.5~15mg/kg, q18h	12.5~15mg/kg, q24h
		60	10~12.5mg/kg, q18h	12.5~15mg/kg, q24h
		90	10~12.5mg/kg, q18h	12.5~15mg/kg, q24h
1.0~1.69	28~31	10	12.5~15mg/kg, q12h	15~17.5mg/kg, q18h
		25	10~12.5mg/kg, q12h	12.5~15mg/kg, q18h
		45	15~17.5mg/kg, q18h	12.5~15mg/kg, q18h
		60	12.5~15mg/kg, q18h	10~12.5mg/kg, q18h
		90	12.5~15mg/kg, q18h	10~12.5mg/kg, q18h
1.7~2.69	32~36	10	15~17.5mg/kg, q12h	12.5~15mg/kg, q12h
		25	12.5~15mg/kg, q12h	10~12.5mg/kg, q12h
		45	10~12.5mg/kg, q12h	15~17.5mg/kg, q18h
		60	10~12.5mg/kg, q12h	12.5~15mg/kg, q18h
		90	10~12.5mg/kg, q12h	12.5~15mg/kg, q18h
2.7~3.69	37~41	10	12.5~15mg/kg, q8h	15~17.5mg/kg, q12h
		25	10~12.5mg/kg, q8h	12.5~15mg/kg, q12h
		45	15~17.5mg/kg, q12h	12.5~15mg/kg, q12h
		60	12.5~15mg/kg, q12h	10~12.5mg/kg, q12h
		90	12.5~15mg/kg, q12h	10~12.5mg/kg, q12h
3.7 ~ 4.6	42~46	10	15~17.5mg/kg, q8h	12.5~15mg/kg, q8h

25	12.5~15mg/kg, q8h	10~12.5mg/kg, q8h
45	10~12.5mg/kg, q8h	15~17.5mg/kg, q12h
60	10~12.5mg/kg, q8h	12.5~15mg/kg, q12h
90	10~12.5mg/kg, q8h	12.5~15mg/kg, q12h

^acWT, current body weight.

722

724 ^bPMA, postmenstrual age.

725 °SCR, serum creatinine.

726 dVAS, vasoactive drugs.